Trial Profile

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
Focus Therapeutic Use

Most Recent Events

09 Sep 2024 Primary endpoint (complete response rate) has been met as per results published in the Cancer Cell
09 Sep 2024 Results published in the Cancer Cell
29 Jan 2023 Planned primary completion date changed from 18 Oct 2021 to 18 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com